These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 27298504)

  • 21. Finasteride Use Is Associated with Higher Odds of Obstructive Sleep Apnea: Results from the US Food and Drug Administration Adverse Events Reporting System.
    Gupta MA; Vujcic B; Gupta AK
    Skinmed; 2020; 18(3):146-150. PubMed ID: 32790610
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of 5α-Reductase Inhibitors With Dementia, Depression, and Suicide.
    Garcia-Argibay M; Hiyoshi A; Fall K; Montgomery S
    JAMA Netw Open; 2022 Dec; 5(12):e2248135. PubMed ID: 36547981
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Impact of 5α-Reductase Inhibitor Use for Male Pattern Hair Loss on Men's Health.
    Said MA; Mehta A
    Curr Urol Rep; 2018 Jun; 19(8):65. PubMed ID: 29909472
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Cardiovascular Safety of Dutasteride.
    Skeldon SC; Macdonald EM; Law MR; Huang A; Paterson JM; Mamdani MM; Juurlink D
    J Urol; 2017 May; 197(5):1309-1314. PubMed ID: 27866006
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Finasteride and Its Potential for the Treatment of Female Pattern Hair Loss: Evidence to Date.
    Iamsumang W; Leerunyakul K; Suchonwanit P
    Drug Des Devel Ther; 2020; 14():951-959. PubMed ID: 32184564
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of dutasteride 0.5 mg/d in men with androgenetic alopecia recalcitrant to finasteride.
    Jung JY; Yeon JH; Choi JW; Kwon SH; Kim BJ; Youn SW; Park KC; Huh CH
    Int J Dermatol; 2014 Nov; 53(11):1351-7. PubMed ID: 24898559
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An observational retrospective evaluation of 79 young men with long-term adverse effects after use of finasteride against androgenetic alopecia.
    Chiriacò G; Cauci S; Mazzon G; Trombetta C
    Andrology; 2016 Mar; 4(2):245-50. PubMed ID: 26763726
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of 5α-Reductase Inhibitor Use on Mortality From Prostate Cancer.
    Figg WD; Thompson IM
    JAMA Oncol; 2015 Jun; 1(3):321-2. PubMed ID: 26181178
    [No Abstract]   [Full Text] [Related]  

  • 29. Investigation of Suicidality and Psychological Adverse Events in Patients Treated With Finasteride.
    Nguyen DD; Marchese M; Cone EB; Paciotti M; Basaria S; Bhojani N; Trinh QD
    JAMA Dermatol; 2021 Jan; 157(1):35-42. PubMed ID: 33175100
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Finasteride and androgenic alopecia; from therapeutic options to medical implications.
    Motofei IG; Rowland DL; Tampa M; Sarbu MI; Mitran MI; Mitran CI; Stoian AP; Diaconu CC; Paunica S; Georgescu SR
    J Dermatolog Treat; 2020 Jun; 31(4):415-421. PubMed ID: 30897009
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A population-based study of the risk of osteoporosis and fracture with dutasteride and finasteride.
    Antoniou T; Macdonald EM; Yao Z; Gomes T; Tadrous M; Ho JM; Mamdani MM; Juurlink DN;
    BMC Musculoskelet Disord; 2018 May; 19(1):160. PubMed ID: 29789004
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Why Odds Ratios Can Be Tricky Statistics: The Case of Finasteride, Dutasteride, and Sexual Dysfunction.
    Andrade C
    J Clin Psychiatry; 2018 Nov; 79(6):. PubMed ID: 30549493
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Research Brief: Self-Reports of a Constellation of Persistent Antiandrogenic, Estrogenic, Physical, and Psychological Effects of Finasteride Usage Among Men.
    Walf AA; Kaurejo S; Frye CA
    Am J Mens Health; 2018 Jul; 12(4):900-906. PubMed ID: 29318957
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comments concerning the real risk of sexual adverse events secondary to the use of 5-ARIs.
    Pirozzi Farina F; Pischedda A
    Arch Ital Urol Androl; 2016 Jan; 87(4):312-6. PubMed ID: 26766804
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Post-finasteride syndrome.
    Pereira AFJR; Coelho TOA
    An Bras Dermatol; 2020; 95(3):271-277. PubMed ID: 32317131
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Finasteride adverse effects in subjects with androgenic alopecia: A possible therapeutic approach according to the lateralization process of the brain.
    Motofei IG; Rowland DL; Georgescu SR; Tampa M; Baconi D; Stefanescu E; Baleanu BC; Balalau C; Constantin V; Paunica S
    J Dermatolog Treat; 2016 Nov; 27(6):495-497. PubMed ID: 27046152
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of the therapeutic effects of AGA drugs by measuring finasteride, dutasteride, and dihydrotestosterone in hair.
    Hobo Y; Nishikawa J; Taniguchi Asai N; Yoneyama K; Watanabe Y; Miyashiro Y; Fujikata A
    Clin Chim Acta; 2023 Jul; 547():117456. PubMed ID: 37385468
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 5α-Reductase inhibitors in androgenetic alopecia.
    Yim E; Nole KL; Tosti A
    Curr Opin Endocrinol Diabetes Obes; 2014 Dec; 21(6):493-8. PubMed ID: 25268732
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical effects and economical impact of dutasteride and finasteride therapy in Italian men with LUTS.
    Cindolo L; Berardinelli F; Fanizza C; Romero M; Pirozzi L; Tamburro FR; Pellegrini F; Neri F; Pitrelli A; Schips L
    Arch Ital Urol Androl; 2013 Dec; 85(4):200-6. PubMed ID: 24399122
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The efficacy and safety of 5α-reductase inhibitors in androgenetic alopecia: a network meta-analysis and benefit-risk assessment of finasteride and dutasteride.
    Gupta AK; Charrette A
    J Dermatolog Treat; 2014 Apr; 25(2):156-61. PubMed ID: 23768246
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.